UMass Chan Medical School scientists develop muscle stem cell technology

UMass Chan Medical School scientists develop muscle stem cell technology
UMass Chan Medical School scientists have developed a skill to separate human skeletal or progenitor muscle stem cells from iPSCs (persuaded pluripotent stem cells).

These patient-derived muscle stem cells, labelled iMyoblasts by researcher Charles P Emerson Jr, PhD, in an eLife article, allow the researchers to chase laboratory research into the initial impacts of disease-causing transformations on muscle functioning and formation.

iMyoblasts, the patient-derived stem cells, are an essential basis for preclinical laboratory models for many identified human muscular dystrophies.

Reports suggest that the technology has the supremacy to develop gene therapy for human muscular dystrophies, leveraging policies including DNA editing, RNA silencing, and stem cell therapy for clinical applications.

Dr Emerson, Professor of neurology, claimed that this is a crucial step for developing gene-editing treatments. He added that Laboratory models of human muscular dystrophy are required for developing these therapeutics before clinical use in patients.

iPSCs can be voluntarily formed in tissue culture by reprogramming a patient’s somatic cells, including muscle and skin biopsy cells, said Emerson.

Using molecules identified to direct muscle cell development during maturation can create muscle antecedent cells that can differentiate into skeletal muscle and imitate themselves to repair or regenerate muscle, he cited.

This becomes a crucial tool in the toolbox given investigating and developing therapeutics for muscular dystrophies.

Moreover, there are around 40 known muscular dystrophies caused by genomic mutations that impact the functioning of muscles. These disorders have mutable ages of onset and clinical severity; however, they often result in premature death or severe physical disabilities.

Over what is said to be decades, patients with muscular dystrophy encounter liberal weakness in the muscle and reduced mobility, making the everyday tasks difficult and frequently impossible to perform even during early disease.

Generally, less than 200,000 cases of muscular dystrophy are diagnosed every year in the United States. However, this protracted disease progression puts a significant long-term burden on the health care systems, patients, and their families.

Source Credit -

About the author



ahadmin has been a part of the content industry for close to two years. Having previously worked as a voice over artist and sportswriter, he now focuses on writing articles for, across a slew of topics, ranging from technology to trade and finance. With a business-oriented educational background, Sunil brings forth the expertise of deep-dive research and a strategic approach in his write ups.